Aptinyx Inc traded at $0.49 this Friday February 3rd, increasing $0.01 or 2.04 percent since the previous trading session. Looking back, over the last four weeks, Aptinyx Inc gained 35.62 percent. Over the last 12 months, its price fell by 84.09 percent. Looking ahead, we forecast Aptinyx Inc to be priced at 0.47 by the end of this quarter and at 0.43 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Daiichi Sankyo 4,087.00 26.00 0.64% 73.14%
Acadia Pharmaceuticals 19.83 -0.08 -0.40% -15.97%
Acorda Therapeutics 0.98 0.01 0.84% -48.10%
Biogen 283.63 -3.89 -1.35% 28.03%
Cara Therapeutics 12.26 0.31 2.59% 15.01%
Halozyme Therapeutics 52.65 -0.22 -0.42% 56.23%
Ionis Pharmaceuticals 40.92 -0.28 -0.68% 29.90%
Intra Cellular Therapies 48.92 -0.82 -1.65% 0.41%
Eli Lilly 339.08 8.38 2.53% 39.96%
Marinus Pharmaceuticals 6.53 -0.13 -1.88% -37.21%
Neurocrine Biosciences 110.03 2.03 1.88% 35.61%
Novartis 79.34 -0.20 -0.25% -1.32%
Ultragenyx Pharmaceutical 45.73 -1.61 -3.40% -33.36%
UCB 75.46 0.36 0.48% -15.16%
Vertex Pharmaceuticals 301.02 -2.76 -0.91% 24.41%

Aptinyx Inc
Aptinyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The Company is targeting and modulating N-methyl-D-aspartate receptors (NMDArs), which are focused on brain and nervous system. It has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. The Company’s lead product candidate, NYX-2925 is in Phase II clinical development for the treatment of chronic pain and enables synaptic plasticity in the brain, a mechanism that is differentiated from any therapy used for the treatment of chronic pain. Its products also include NYX-783, which is in Phase II clinical development for the treatment of post-traumatic stress disorder, and NYX-458 is in Phase II clinical development for the treatment of cognitive impairment associated.